Results 161 to 170 of about 2,602 (175)

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study. [PDF]

J Clin Transl Hepatol
Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, Toyoda H, Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, Atsukawa M, Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CP, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VW, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwara E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Xuan Tay W, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH.   +100 more
europepmc   +1 more source

Internal Medicine (3) [PDF]

, 2017
三原 弘, 南條 宗八, 吉田 裕紀, 和田 暁法, 在田 幸太郎, 安村 敏, 安藤 孝将, 峯村 正実, 杉山 敏郎, 村上 純, 梶浦 新也, 田尻 和人, 細川 歩, 藤浪 斗, 高原 照美   +14 more
core   +2 more sources

FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy. [PDF]

Discov Oncol
Pramanik S, Thaker M, Inoue N, Kim PS, Kutzner A, Manavalan A, Pramanik G, Heese K.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Asunaprevir/daclatasvir

Reactions Weekly, 2016
  +15 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2018
  +12 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2017
  +11 more sources

Daclatasvir + Asunaprevir: First Global Approval

Drugs, 2014
The combination of daclatasvir + asunaprevir [Daklinza(®) + Sunvepra(®) (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.
openaire   +2 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2015
  +4 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2022
openaire   +2 more sources